MiRNA182 regulates percentage of myeloid and erythroid cells in chronic myeloid leukemia

Cell Death Dis. 2017 Jan 12;8(1):e2547. doi: 10.1038/cddis.2016.471.

Abstract

The deregulation of lineage control programs is often associated with the progression of haematological malignancies. The molecular regulators of lineage choices in the context of tyrosine kinase inhibitor (TKI) resistance remain poorly understood in chronic myeloid leukemia (CML). To find a potential molecular regulator contributing to lineage distribution and TKI resistance, we undertook an RNA-sequencing approach for identifying microRNAs (miRNAs). Following an unbiased screen, elevated miRNA182-5p levels were detected in Bcr-Abl-inhibited K562 cells (CML blast crisis cell line) and in a panel of CML patients. Earlier, miRNA182-5p upregulation was reported in several solid tumours and haematological malignancies. We undertook a strategy involving transient modulation and CRISPR/Cas9 (clustered regularly interspersed short palindromic repeats)-mediated knockout of the MIR182 locus in CML cells. The lineage contribution was assessed by methylcellulose colony formation assay. The transient modulation of miRNA182-5p revealed a biased phenotype. Strikingly, Δ182 cells (homozygous deletion of MIR182 locus) produced a marked shift in lineage distribution. The phenotype was rescued by ectopic expression of miRNA182-5p in Δ182 cells. A bioinformatic analysis and Hes1 modulation data suggested that Hes1 could be a putative target of miRNA182-5p. A reciprocal relationship between miRNA182-5p and Hes1 was seen in the context of TK inhibition. In conclusion, we reveal a key role for miRNA182-5p in restricting the myeloid development of leukemic cells. We propose that the Δ182 cell line will be valuable in designing experiments for next-generation pharmacological interventions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Lineage / genetics
  • Cell Proliferation / genetics*
  • Drug Resistance, Neoplasm / genetics
  • Erythroid Cells / metabolism
  • Erythroid Cells / pathology
  • Fusion Proteins, bcr-abl / genetics
  • Gene Expression Regulation, Leukemic / drug effects
  • Humans
  • K562 Cells
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism
  • Myeloid Cells / metabolism
  • Myeloid Cells / pathology
  • Protein Kinase Inhibitors / therapeutic use
  • Transcription Factor HES-1 / biosynthesis
  • Transcription Factor HES-1 / genetics*

Substances

  • MicroRNAs
  • Mirn182 microRNA, human
  • Protein Kinase Inhibitors
  • Transcription Factor HES-1
  • HES1 protein, human
  • Fusion Proteins, bcr-abl